Medications for Pulmonary Arterial Hypertension

12 results

  • adcirca - tadalafil tablet

    (Tadalafil)
    United Therapeutics Corporation
    Adcirca is indicated for pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability, primarily studied in NYHA Functional Class II–III patients with idiopathic, heritable, or connective tissue disease-associated PAH.
    Medication Details
    Drug Interactions

  • adempas - riociguat tablet, film coated

    (Riociguat)
    Bayer Healthcare Pharmaceuticals Inc.
    Adempas treats adults with persistent/recurrent or inoperable chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) and pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capacity, WHO functional class, and delay clinical worsening.
    Medication Details
    Drug Interactions

  • letairis - ambrisentan tablet, film coated

    (Ambrisentan)
    Gilead Sciences, Inc.
    Letairis treats pulmonary arterial hypertension (PAH, WHO Group 1) in adults to improve exercise ability and delay clinical worsening. Combined with tadalafil, it reduces disease progression risk and hospitalization. Studied primarily in WHO Functional Class II–III patients with idiopathic, heritable, or connective tissue disease-associated PAH.
    Medication Details
    Drug Interactions

  • opsumit - macitentan tablet, film coated

    (Macitentan)
    Actelion Pharmaceuticals Us, Inc.
    Opsumit treats pulmonary arterial hypertension (PAH, WHO Group I) in adults, reducing the risk of disease progression and hospitalization. Effective in WHO Functional Class II–III patients, including idiopathic, heritable, connective tissue disorder-associated, and congenital heart disease-associated PAH.
    Medication Details
    Drug Interactions

  • orenitram - treprostinil tablet, extended release

    (Treprostinil)
    United Therapeutics Corporation
    Orenitram treats pulmonary arterial hypertension (PAH) in adults (WHO Group 1) to delay disease progression and improve exercise capacity. Most studied in WHO functional class II-III patients with idiopathic, heritable, or connective tissue disease-associated PAH.
    Medication Details
    Drug Interactions

  • revatio - sildenafil citrate tablet, film coated

    (Sildenafil Citrate)
    Pfizer Laboratories Div Pfizer Inc
    Revatio treats pulmonary arterial hypertension (PAH, WHO Group I) in adults to improve exercise ability and delay clinical worsening. Also indicated for pediatric patients aged 1–17 years to improve exercise ability and pulmonary hemodynamics.
    Medication Details
    Savings Programs
    1
    Drug Interactions

  • tadliq - tadalafil suspension

    (Tadalafil)
    Cmp Pharma, Inc.
    TADLIQ is a PDE5 inhibitor indicated for pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise ability, primarily in adults with NYHA Functional Class II–III symptoms from idiopathic, heritable, or connective tissue disease-associated PAH.
    Medication Details
    Drug Interactions

  • tracleer - bosentan tablet, film coated

    (Bosentan)
    Actelion Pharmaceuticals Us, Inc.
    Tracleer treats pulmonary arterial hypertension (PAH) in adults to improve exercise ability and slow disease progression, and in children 3+ years with idiopathic or congenital PAH to reduce pulmonary vascular resistance.
    Medication Details
    Drug Interactions

  • tyvaso - treprostinil inhalant

    (Treprostinil)
    United Therapeutics Corporation
    Tyvaso treats pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) in adults to improve exercise ability.
    Medication Details
    Drug Interactions

  • uptravi - selexipag tablet, coated

    (Selexipag)
    Actelion Pharmaceuticals Us, Inc.
    Uptravi (selexipag) treats pulmonary arterial hypertension (PAH, WHO Group I) in adults to delay disease progression and reduce hospitalization risk. Studied in patients with WHO Functional Class II–III symptoms, including idiopathic, heritable, connective tissue disease-associated, and congenital heart disease-associated PAH.
    Medication Details
    Drug Interactions